Predicting the intrinsic insensitivity of some ATC to CDK4/6i might be important because, like RB-deficient tumors in other cancers such as small cell lung cancers (SCLC), they might respond particularly well to genotoxic chemotherapy (89, 90). The gene discussed is CDK4; the disease is cancer.